Two very under the radar but important announcements by ResApp.
I know many will be relieved to see US muscle being added to the new advisory board, especially a professor from Harvard Medical School.
The existing board has taken us so far but the next phase requires experienced and reputable personnel with commercial experience. Peer reviewed journal is further validating the commercial utility of the technology to medical professionals.
News coverage has also been a plus, this PR uptick might create the perfect storm for a re-rate of the equity come CE mark.
Ann: Paediatric Study Published In Peer-Reviewed Journal, page-24
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #